{"entity":{"id":"paper-worthington-precede-early-detection-biomarkers-ijc-2026","kind":"paper","name":"Pancreatic cancer early detection biomarkers for high-risk individuals: insights from the PRECEDE consortium","aka":[],"tldr":"A review from the PRECEDE consortium of what might catch pancreatic cancer early in people at high risk: imaging remains the backbone, cyst fluid and pancreatic juice add specificity, and blood, microbiome and multi-omic markers are still research because early lesions shed too little to measure.","summary":"Efforts in early detection have centred on imaging features and liquid biopsy biomarkers able to detect pancreatic ductal adenocarcinoma and its high-grade precursors before symptoms in people at elevated risk. Classical imaging-based surveillance aligned with current guidelines forms the foundation, while organ-specific fluid analyses such as cyst fluid and pancreatic juice offer complementary tools with enhanced specificity. Advances in radiomics, liquid biopsy, microbiome and multi-omics profiling are expanding the field, but precursor lesions are difficult to diagnose non-invasively, are often not visible radiologically or endosonographically and cannot be definitively graded before resection; early-stage neoplasias release low levels of many biomarkers and thresholds defining malignant transformation remain poorly established. The PRECEDE international cohort study of high-risk individuals was designed to discover and validate diagnostic biomarkers under the PROBE study design.","asOf":"2026-09-24","links":[{"label":"Worthington et al., Int J Cancer 2026: early detection biomarkers for high-risk individuals, PRECEDE","url":"https://doi.org/10.1002/ijc.70592"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/42298760/"}],"tags":[],"related":[],"cancers":["pancreatic","ipmn-cystic-precursors"],"sections":[],"technologies":["pancreatic-surveillance","liquid-biopsy","mced","proteomics","methylation-profiling"],"targets":[],"drugs":[],"companies":[],"institutions":["nyu-perlmutter","sheba"],"pathways":[],"terms":["ca19-9","cfdna"],"trials":["precede"],"people":["diane-simeone","talia-golan"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"journal":"International Journal of Cancer","year":2026,"doi":"10.1002/ijc.70592","pmid":"42298760","authors":"Worthington C, Raitses-Gurevich M, Innamorati G, et al.","paperType":"review","findings":["Imaging surveillance remains the foundation; cyst fluid and pancreatic juice add specificity.","Early lesions shed too little for current blood markers and transformation thresholds are unestablished."],"whatItMeans":"The current honest statement of where early detection stands: no blood test is ready, and the research is about finding the threshold at which to operate.","caveats":["Review; the PRECEDE cohort's own biomarker results are not yet reported.","High-risk individuals only, not population screening."],"changedPractice":false},"route":"/key-papers/paper-worthington-precede-early-detection-biomarkers-ijc-2026/","neighbours":{"cancer":[{"id":"ipmn-cystic-precursors","kind":"cancer","name":"Intraductal papillary mucinous neoplasm and other pancreatic cystic precursors","route":"/cancers/ipmn-cystic-precursors/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"technology":[{"id":"methylation-profiling","kind":"technology","name":"DNA methylation profiling","route":"/technologies/methylation-profiling/"},{"id":"pancreatic-surveillance","kind":"technology","name":"High-risk pancreatic surveillance (CAPS / PRECEDE)","route":"/technologies/pancreatic-surveillance/"},{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"mced","kind":"technology","name":"Multi-cancer early detection (MCED)","route":"/technologies/mced/"},{"id":"proteomics","kind":"technology","name":"Proteomics & phosphoproteomics","route":"/technologies/proteomics/"}],"institution":[{"id":"nyu-perlmutter","kind":"institution","name":"Laura and Isaac Perlmutter Cancer Center at NYU Langone Health","route":"/institutions/nyu-perlmutter/"},{"id":"sheba","kind":"institution","name":"Sheba Medical Center","route":"/institutions/sheba/"}],"term":[{"id":"ca19-9","kind":"term","name":"CA 19-9","route":"/terms/ca19-9/"},{"id":"cfdna","kind":"term","name":"Cell-free DNA (cfDNA)","route":"/terms/cfdna/"}],"trial":[{"id":"precede","kind":"trial","name":"PRECEDE","route":"/trials/precede/"}],"person":[{"id":"diane-simeone","kind":"person","name":"Diane M. Simeone","route":"/people/diane-simeone/"},{"id":"talia-golan","kind":"person","name":"Talia Golan","route":"/people/talia-golan/"}]}}